Quarterly report pursuant to Section 13 or 15(d)

Stock Warrants

v3.20.2
Stock Warrants
9 Months Ended
Sep. 30, 2020
Text Block [Abstract]  
Stock Warrants
9. Stock Warrants
As of September 30, 2020 and December 31, 2019, the Company had warrants outstanding as shown in the table below.
 
 
  
September 30,

2020
 
  
December 31,

2019
 
2020 Warrants
     8,842,464        —    
2017 Warrants
     1,599,645        1,599,645  
2016 Warrants
     1,400,000        1,400,000  
Pfizer Warrant
     505,617        —    
Placement Agent Warrants
     —          18,915  
Other warrants (1)
     6,854        15,350  
Warrants to purchase common stock
     12,354,580        3,033,910  
  
 
 
    
 
 
 
Weighted-average exercise price per share
   $ 9.16      $ 22.61  
  
 
 
    
 
 
 
 
(1)
Other warrants are comprised of warrants issued prior to the Company’s IPO, generally in exchange for services rendered to the Company.
The following table summarizes information regarding the Company’s warrants outstanding at September 30, 2020:
 
Exercise Prices
  
Shares
Underlying
Outstanding
Warrants
    
Expiration Date
£
$10.00
     9,348,652      September 1, 2021
 
 
May 27, 2023
$10.01 - $19.99
     1,599,645      July 25, 2022
³
$20.00
     1,406,283      October 26, 2020 – January 5, 2022
  
 
 
    
     12,354,580